To further explore the responsiveness of MM to DUB inhibition, two additional primary samples (MM14 and MM90) from myeloma patients as first relapse were tested for their capacity of inducing ISG upon PR619 treatment. Here, ZUP1 is linked to plasma cell myeloma.